Kannalife is a pharmaceutical firm specializing in the exploration and advancement of a series of innovative cannabinoid treatments to address the needs of patients with significant medical requirements. Over the past ten years, Kannalife has established itself as a pioneer in researching and discovering new therapeutic agents derived from cannabinoids to address conditions such as Chemotherapy Induced Peripheral Neuropathy (CIPN), Hepatic Encephalopathy (HE), Mild Traumatic Brain Injury (mTBI), and the management of chronic pain.